Showing 8 posts of 8 posts found.

Alnylam and Roche partner for RNAi therapeutic for treatment of hypertension

July 24, 2023
Research and Development Alnylam, Cardiology, Roche, hypertension, rnai, zilebesiran

Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the development and commercialisation of zilebesiran, …

Alnylam cuts workforce by a third

January 23, 2012
Research and Development, Sales and Marketing Alnylam, Novartis, job cuts, rnai

Alnylam will cut 33% of its workforce this year as it looks to focus on developing its own products. The …

The RNA interference process

RNA interference – still the great white hope?

March 3, 2011
Manufacturing and Production, Research and Development RNA interference, rnai

The emerging field of RNA interference – also known as ‘gene silencing’ – is one of the most promising in …

Success in pre-clinical microRNA treatment of prostate cancer

January 19, 2011
Research and Development MD Anderson Cancer Center, MicroRNA, Mirna Therapeutics, RNA interfering, miRNA, prostate cancer, rnai

A new MicroRNA treatment for prostate cancer has been highly effective against the disease in pre-clinical studies. MicroRNAs, or miRNAs, …

Novartis and Quark sign gene silencing deal

August 19, 2010
Research and Development Novartis, Quark, SiRNA, rnai

Novartis has joined the race to develop a ‘gene silencing’ treatment by signing a new deal with siRNA specialist Quark …

Silence Therapeutics promotes Jorg Kaufmann

May 21, 2010
Research and Development Silence Therapeutics, appointment, research and development, rnai

Jorg Kaufmann has been made vice president of research at UK biotech company Silence Therapeutics. He previously served as senior …

RNA Interference using nanoparticles hits target in human patients

April 29, 2010
Research and Development SiRNA, nanoparticles, rnai

US researchers have shown that a targeted nanoparticle can penetrate cancer cells in order to deliver small interfering RNAs (siRNAs), …

Latest news from Datamonitor

February 6, 2008
Sales and Marketing Coronado Biosciences, rnai

 Coronado Biosciences’ cancer treatment effective in animal modelsCoronado Biosciences has reported that the Bcl-2 inhibitor, apogossypol, effectively killed a variety …

Latest content